Myriad Genetics Says US Patent And Trademark Office Has Granted Patent That Covers Use Of Push-Button Blood Collection Devices For PCR-Based Fetal Sex Determination
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics announced that the US Patent and Trademark Office has granted a patent covering the use of push-button blood collection devices for PCR-based fetal sex determination. The patent, U.S. Patent No. 11,932,907, titled 'Fetal Sex Determination Using Capillary Blood From Upper Arm,' protects Myriad's SneakPeek Snap products in the U.S through 2040.
March 20, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Myriad Genetics has been granted a patent for their SneakPeek Snap products, ensuring protection for their fetal sex determination technology in the U.S through 2040.
The granting of a patent for Myriad Genetics' SneakPeek Snap products is a significant development, as it not only secures the company's intellectual property rights but also potentially strengthens its competitive position in the market for fetal sex determination technologies. This protection through 2040 could enhance investor confidence in the company's long-term prospects and innovation capabilities, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100